drug
ARTESUNATE
Marketedupdated 3mo agoby Artasome Therapeutics LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 1indications
investigational
Pulmonary Fibrosis
all catalysts(6)
approval · 6
May 26, 2020
approval
ARTESUNATE — FDA approval
ARTESUNATE
→
Feb 4, 2022
approval
ARTESUNATE — FDA approval
ARTESUNATE
→
Mar 3, 2023
approval
ARTESUNATE — FDA approval
ARTESUNATE
→
Jul 31, 2023
approval
ARTESUNATE — FDA approval
ARTESUNATE
→
Jan 16, 2025
approval
ARTESUNATE — FDA approval
ARTESUNATE
→
Apr 13, 2026
approval
ARTESUNATE — FDA approval
ARTESUNATE
→
Trials studying ARTESUNATE
- phase2Study Evaluating the Efficacy and Safety of Artesunate
- phase2To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria
- phase2Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
- phase1Artesunate Pessaries (Vaginal Inserts) for Cervical Precancer in Kenya
- phase2Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)
- phase2Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/ III Colorectal Cancer
- phase2Safety and Efficacy of Oral Artesunate for Pre-cervical Cancer
- phase2Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 26, 2027
278 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Feb 16, 2044formulationUS 12121506
- Feb 16, 2044method-of-use (U-4433)US 12390442
FDA exclusivities (1)
- May 26, 2027ODE-290Orphan Drug (7y)278d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1m ago
Found something off?
comments(0)
5-min edit window · permanent after that